<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643863</url>
  </required_header>
  <id_info>
    <org_study_id>ML28202</org_study_id>
    <nct_id>NCT01643863</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (MONACO)</brief_title>
  <official_title>A Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (TCZ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center observational study will evaluate the use of RoActemra/Actemra&#xD;
      (tocilizumab) in monotherapy in patients with rheumatoid arthritis. Eligible patients&#xD;
      initiated on RoActemra/Actemra treatment according to the licensed label will be followed for&#xD;
      6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients on RoActemra/Actemra at 6 months</measure>
    <time_frame>approximately 20 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of dose modifications/interruptions</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Response according to total joint count evaluation by DAS28/EULAR/SDAI/CDAI/ACR</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of disease activity</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes: Health Assessment Questionnaires</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Introduction/use of disease-modifying anti-rheumatic drugs (DMARDs)</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reduction/withdrawal of corticosteroids</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events\n</measure>
    <time_frame>approximately 20 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra in&#xD;
        monotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients, &gt;/= 18 years of age&#xD;
&#xD;
          -  Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria&#xD;
&#xD;
          -  Patients in whom the treating physician has made the decision to commence&#xD;
             RoActemra/Actemra treatment in monotherapy, in case of methotrexate intolerance or&#xD;
             when continuous methotrexate treatment is inadequate (in accordance with the local&#xD;
             label), and who have received (or started) RoActemra/Actemra monotherapy treatment&#xD;
             within 8 weeks prior to the enrolment visit.&#xD;
&#xD;
          -  Concomitant corticosteroids (oral or intra-articular) or non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) are allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in whom RoActemra/Actemra is contraindicated according to the approved&#xD;
             Summary of Product Characteristics&#xD;
&#xD;
          -  Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment&#xD;
             visit&#xD;
&#xD;
          -  Patients who have previously received RoActemra/Actemra in a clinical trial or for&#xD;
             compassionate use&#xD;
&#xD;
          -  Concomitant DMARD treatment for rheumatoid arthritis (e.g. hydroxychloroquine,&#xD;
             sulfasalazine, methotrexate, leflunomide, gold compounds, cyclosporine) when starting&#xD;
             treatment with RoActemra/Actemra&#xD;
&#xD;
          -  Treatment with any investigational agent within 4 weeks (or 5 half-lives of the&#xD;
             investigational agent, whichever is longer) before starting treatment with&#xD;
             RoActemra/Actemra&#xD;
&#xD;
          -  History of autoimmune disease or any joint inflammatory disease other than rheumatoid&#xD;
             arthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1069-639</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

